Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer

Immune checkpoint blockade (ICB) is an approved therapy for advanced metastatic mismatch repair (MMR)‐deficient cancer regardless of tissue of origin. Although therapy is effective initially, recurrence rates are significant, and long‐term outcomes remain poor for most patients. It is not currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Winer, Arthur, Ghatalia, Pooja, Bubes, Nicole, Anari, Fern, Varshavsky, Asya, Kasireddy, Vineela, Liu, Yang, El‐Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Precision Medicine Clinic: Molecular Tumor Boards
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853126/
https://www.ncbi.nlm.nih.gov/pubmed/31444293
http://dx.doi.org/10.1634/theoncologist.2018-0686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853126/
https://www.ncbi.nlm.nih.gov/pubmed/31444293
http://dx.doi.org/10.1634/theoncologist.2018-0686

Ejemplares similares